NasdaqGS:CRNXPharmaceuticals
Crinetics Pharmaceuticals (CRNX) Stock Looks Fully Valued While Returns Stay Very Strong
Crinetics Pharmaceuticals has delivered very large 5 year returns while recent valuation checks suggest the stock now leans expensive on traditional multiples, leaving investors weighing a powerful run against a less clear margin of safety at around US$83.91 per share.
Over the past 5 years, Crinetics Pharmaceuticals has returned about 326%, which puts current holders in a strong position and raises the bar for any further upside to be justified by fundamentals.
The proposed US$85 per share...